Download PDF
Thromb Haemost 1997; 78(01): 210-213
DOI: 10.1055/s-0038-1657528
Clinical trials with anti IIb/IIIa inhibitors in acute coronary syndromes
Schattauer GmbH Stuttgart

Clinical Trials with Glycoprotein IIb/IIIa Receptor Antagonists in Acute Coronary Syndromes

Frans Van de Werf
Department of Cardiology, University of Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250
    CrossrefPubMedGoogle Scholar
  • 2 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1192; 326: 310-318
    PubMedGoogle Scholar
  • 3 DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural mocardial infarction. N Engl J Med 1980; 303: 897-902
    CrossrefPubMedGoogle Scholar
  • 4 DeWood MA, Stifter WF, Simpson CA, Spores J, Eugster GS, Judge TP, Hinnen ML. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417-423
    CrossrefPubMedGoogle Scholar
  • 5 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
    CrossrefPubMedGoogle Scholar
  • 6 Collins R, Mac Mahons, Flather M. et al Clincal effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med 1996; 313: 652-659
    CrossrefPubMedGoogle Scholar
  • 7 Ridker PM, Hebert PR, Fuster V, Henneken CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?. Lancet 1993; 341: 1574-1577
    CrossrefPubMedGoogle Scholar
  • 8 RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-830
    CrossrefPubMedGoogle Scholar
  • 9 Holdright D. et al Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39-45
    CrossrefPubMedGoogle Scholar
  • 10 Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992; 327: 141-145
    CrossrefPubMedGoogle Scholar
  • 11 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294
    CrossrefPubMedGoogle Scholar
  • 12 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559
    CrossrefPubMedGoogle Scholar
  • 13 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
    CrossrefPubMedGoogle Scholar
  • 14 Agruirre FV, Topol E, Furguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM. Bleeding complications with the chimeric antibody to platelet GPIIb/IIIa Integrin in patients undergoing perculaneous coronary intervention. Circulation 1995; 91: 2882-2890
    CrossrefPubMedGoogle Scholar
  • 15 Topol EF, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M. et al Randomised trial of coronary intervention with antibody against platelet lib/ Ilia integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343: 881-886
    CrossrefPubMedGoogle Scholar
  • 16 Van de Werf. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. Eur Heart J 1996; 17: 325-326
    CrossrefPubMedGoogle Scholar
  • 17 Tcheng JE, Lincoff AM, Sigmon KN, Kitt MM, Califf RM, Topol EF. for the IMPACT II Investigators Platelet glycoproteinHb/nia inhibition with Integrelin during percutaneous coronary intervention: the IMPACT II Trial. Circulation 1995; 92 (suppl) 001-543
    CrossrefPubMedGoogle Scholar
  • 18 King III SB. Administration of Tirofiban (MK-0383) will reduce the incidence of adverse cardiac outcome following PTCA/ DCA (RESTORE). J Am Coll Cardiol 1996; 27: 001-543 (suppl A)
    PubMedGoogle Scholar
  • 19 Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 04: 252-261
    CrossrefPubMedGoogle Scholar
  • 20 CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-1338
    CrossrefPubMedGoogle Scholar
  • 21 De ClerckF, Beertens J, De Chaffoy, de Courcelles D, Freyne E, Janssn PAJ. R68070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. I. Biochemical profile in vitro. Thromb Haemostas 1989; 61: 35-42
    PubMedGoogle Scholar
  • 22 The RAPT investigators: Randomized Trial of Ridogrel, a Combined Thromboxane A2 Synthase Inhibitor and Thromboxane A2/Prostaglandin Endoperoxide Receptor Antagonist, Versus Aspirin as Adjunct to Thrombolysis in Patients With Acute Myocardial Infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 588-595
    CrossrefPubMedGoogle Scholar